To conquer brain tumors, strong collaboration with an active private sector is needed. To help bridge this gap between scientific discovery at academic-based institutions and commercial product development — often referred to as the “Valley of Death” — the Brain Tumor Investment Fund raises philanthropic capital and uses our team’s expertise and experience to incentivize biotechnology, pharmaceutical, and medical device companies around the world to develop new treatments and motivate additional private financing. We hope to galvanize a thriving investment market to deliver new therapeutics and diagnostics that will improve the lives of brain tumor patients.
The Brain Tumor Investment Fund offers a unique platform for philanthropists interested in high-impact equity investing to stimulate a portfolio of innovative companies and products that are both financially attractive and that align with our mission to conquer and cure brain tumors.
We possess the right scientific breadth of expertise to identify potential transformative technologies and support them in their development to become novel treatments and cures for patients. Investment in brain cancer companies will accelerate and advance the commercial development of novel therapeutics in this space.
As a venture philanthropy fund, neither management nor donors to the fund receive distributions. All profits are recycled back into the fund for further investment by the Brain Tumor Investment Fund, creating a self-sustaining enterprise capable of targeting emerging opportunities to advance new treatments, attract new biopharmaceutical companies to the field, foster innovation, and build a pipeline of future therapies urgently needed for patients.
In 2021, Drug Discovery Today published a paper on this topic entitled “Accelerating glioblastoma therapeutics via venture philanthropy”. Read the complete paper to learn why “a portfolio-based strategy for the parallel discovery of breakthrough therapies can effectively reduce the financial risks of potentially transformative clinical trials for GBM.”